Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APVO OTCMKTS:CRPOF NASDAQ:GHSI OTCMKTS:MCUJF NASDAQ:UMRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$1.50+4.2%$2.26$1.40▼$381.10$4.73M5.77175,661 shs114.04 million shsCRPOFCeapro$0.17$0.17$0.11▼$0.40$13.31M1.4715,466 shsN/AGHSIGuardion Health Sciences$3.22-2.1%$3.24$3.04▼$18.00$4.35M0.73105,261 shs4,700 shsMCUJFMedicure$0.71-14.6%$0.84$0.44▼$0.94$8.62M1.1543 shs444 shsUMRXCogent Biosciences$12.54+1.0%$10.50$0.29▼$3.72$532.56M3.931.22 million shs1.14 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics+4.17%-1.96%-25.00%-70.76%-99.98%CRPOFCeapro0.00%0.00%0.00%0.00%0.00%GHSIGuardion Health Sciences0.00%0.00%0.00%0.00%-67.44%MCUJFMedicure-14.59%-10.64%-25.20%-13.96%-11.81%UMRXCogent Biosciences-1.97%-2.13%+4.37%+62.86%+16.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$1.50+4.2%$2.26$1.40▼$381.10$4.73M5.77175,661 shs114.04 million shsCRPOFCeapro$0.17$0.17$0.11▼$0.40$13.31M1.4715,466 shsN/AGHSIGuardion Health Sciences$3.22-2.1%$3.24$3.04▼$18.00$4.35M0.73105,261 shs4,700 shsMCUJFMedicure$0.71-14.6%$0.84$0.44▼$0.94$8.62M1.1543 shs444 shsUMRXCogent Biosciences$12.54+1.0%$10.50$0.29▼$3.72$532.56M3.931.22 million shs1.14 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics+4.17%-1.96%-25.00%-70.76%-99.98%CRPOFCeapro0.00%0.00%0.00%0.00%0.00%GHSIGuardion Health Sciences0.00%0.00%0.00%0.00%-67.44%MCUJFMedicure-14.59%-10.64%-25.20%-13.96%-11.81%UMRXCogent Biosciences-1.97%-2.13%+4.37%+62.86%+16.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPVOAptevo Therapeutics 3.00Buy$219,040.0014,602,566.67% UpsideCRPOFCeapro 0.00N/AN/AN/AGHSIGuardion Health Sciences 0.00N/AN/AN/AMCUJFMedicure 0.00N/AN/AN/AUMRXCogent Biosciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPVOAptevo Therapeutics$3.11M1.59N/AN/A$65.21 per share0.02CRPOFCeapro$7.14M1.86$0.06 per share2.74$0.32 per share0.53GHSIGuardion Health Sciences$12.25M0.35$0.14 per share23.15$6.39 per share0.50MCUJFMedicure$15.99M0.46$0.08 per share9.26$1.45 per share0.49UMRXCogent Biosciences$22.50M23.67N/AN/A$1.04 per share12.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPVOAptevo Therapeutics-$24.13MN/A0.00N/AN/AN/A-675.52%-175.68%11/6/2025 (Estimated)CRPOFCeapro-$3.49M-$0.06N/A∞N/A-69.60%-20.30%-18.07%N/AGHSIGuardion Health Sciences$160K$4.870.66∞N/A22.79%-73.69%-48.17%N/AMCUJFMedicure-$760K-$0.10N/A∞N/A-5.70%-6.65%-4.52%11/24/2025 (Estimated)UMRXCogent Biosciences-$31.83M-$1.04N/AN/AN/A-96.84%-87.78%-52.14%N/ALatest APVO, CRPOF, MCUJF, GHSI, and UMRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/20/2025Q2 2025MCUJFMedicureN/A-$0.06N/A-$0.06N/A$4.82 million8/11/2025Q2 2025APVOAptevo Therapeutics-$83.20-$8.40+$74.80-$8.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPVOAptevo TherapeuticsN/AN/AN/AN/AN/ACRPOFCeaproN/AN/AN/AN/AN/AGHSIGuardion Health Sciences$5.00155.28%N/A102.67%N/AMCUJFMedicureN/AN/AN/AN/AN/AUMRXCogent BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPVOAptevo TherapeuticsN/A2.272.27CRPOFCeaproN/A11.007.72GHSIGuardion Health SciencesN/A16.6816.59MCUJFMedicure0.031.481.06UMRXCogent Biosciences0.182.902.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPVOAptevo Therapeutics8.06%CRPOFCeaproN/AGHSIGuardion Health Sciences20.21%MCUJFMedicureN/AUMRXCogent Biosciences26.39%Insider OwnershipCompanyInsider OwnershipAPVOAptevo Therapeutics0.12%CRPOFCeaproN/AGHSIGuardion Health Sciences1.32%MCUJFMedicure12.90%UMRXCogent Biosciences31.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPVOAptevo Therapeutics503.29 million3.28 millionNot OptionableCRPOFCeaproN/A78.29 millionN/ANot OptionableGHSIGuardion Health Sciences101.35 million1.33 millionNot OptionableMCUJFMedicureN/A10.44 million9.09 millionNot OptionableUMRXCogent Biosciences7242.47 millionN/ANot OptionableAPVO, CRPOF, MCUJF, GHSI, and UMRX HeadlinesRecent News About These CompaniesCogent Biosciences price target raised to $20 from $17 at GuggenheimAugust 25, 2025 | msn.comCogent Biosciences Rated as a Buy at Citi on Robust PipelineJuly 25, 2025 | msn.comCogent Biosciences Scores Analyst Praise As Mastocytosis Drug Hits Trial Goals; Retail Buzz SurgesJuly 9, 2025 | msn.comCogent's Chronic Immune Disorder Drug Has Strong Potential To Become A Blockbuster: AnalystJuly 8, 2025 | benzinga.comCogent Biosciences, Inc. Announces Underwritten Public Offering of $150 Million in Common StockJuly 8, 2025 | quiverquant.comQCogent Jumps on Positive Mid-Stage Mastocytosis Data and NDA PlansJuly 8, 2025 | biospace.comBStudy results boost Cogent’s case for rare disease drugJuly 8, 2025 | biopharmadive.comBCogent Biosciences Shares Rise After Mastocytosis Treatment Reaches Primary Endpoint in Recent StudyJuly 7, 2025 | marketwatch.comCogent’s phase 3 hits primary endpoint, building case for filing to challenge Blueprint’s AyvakitJuly 7, 2025 | fiercebiotech.comFCogent Biosciences Jumps 10% After Bezuclastinib Trial Delivers Strong ResultsJuly 7, 2025 | msn.comCogent surges as bezuclastinib meets key goal in phase 2 mastocytosis trialJuly 7, 2025 | msn.comCogent Biosciences drug improves symptoms of chronic immune disorder, study results showJuly 7, 2025 | statnews.comSCogent Biosciences Reports Positive SUMMIT Trial Results for Bezuclastinib in Non-Advanced Systemic Mastocytosis, Prepares for FDA NDA SubmissionJuly 7, 2025 | quiverquant.comQCogent Biosciences Secures $400 Million Debt Financing Facility to Support Growth and Upcoming Bezuclastinib LaunchJune 11, 2025 | quiverquant.comQWhy Cogent Biosciences (COGT) Is One of the Best Low Priced Biotech Stocks to Buy NowMay 13, 2025 | insidermonkey.comCogent Biosciences Advances with Promising Clinical TrialsMay 6, 2025 | tipranks.comIs Cogent Biosciences, Inc. (COGT) the Best Small Cap Stock to Buy with the Biggest Upside Potential?May 5, 2025 | insidermonkey.comCogent Biosciences (COGT): Among the Most Promising Penny Stocks According to AnalystsApril 20, 2025 | insidermonkey.comIs Cogent Biosciences Inc. (NASDAQ:COGT) the Best Biotech Penny Stock to Buy According to Hedge Funds?April 17, 2025 | msn.comCogent Biosciences (COGT): Among the Best Biotech Stocks to Buy According to BillionairesMarch 18, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPVO, CRPOF, MCUJF, GHSI, and UMRX Company DescriptionsAptevo Therapeutics NASDAQ:APVO$1.50 +0.06 (+4.17%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$1.50 0.00 (-0.33%) As of 04:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Ceapro OTCMKTS:CRPOF$0.17 0.00 (0.00%) As of 06/6/2024Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.Guardion Health Sciences NASDAQ:GHSIGuardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.Medicure OTCMKTS:MCUJF$0.71 -0.12 (-14.59%) As of 09/16/2025 01:13 PM EasternMedicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.Cogent Biosciences NASDAQ:UMRXCogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
